share_log

Mangoceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mangoceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mangoceuticals | S-8：员工福利计划证券登记
美股sec公告 ·  05/14 09:04
Moomoo AI 已提取核心信息
On May 14, 2024, Mangoceuticals, Inc., a Texas-based pharmaceutical company, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). The filing is intended to register an additional 7,831,500 shares of common stock under the company's Amended and Restated 2022 Equity Incentive Plan. This move comes after an amendment to the plan that increased the number of shares reserved for issuance by 5,831,500, effective March 25, 2024, and an automatic increase of 2,000,000 shares effective April 1, 2024. The registration statement incorporates by reference several previously filed documents, including the company's Annual Report on Form 10-K for the year ended December 31, 2023, and various Current Reports on Form 8-K. The validity of the common stock covered by this prospectus has been passed upon by The Loev Law Firm, PC. The CEO and Chairman of Mangoceuticals, Jacob D. Cohen, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
On May 14, 2024, Mangoceuticals, Inc., a Texas-based pharmaceutical company, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). The filing is intended to register an additional 7,831,500 shares of common stock under the company's Amended and Restated 2022 Equity Incentive Plan. This move comes after an amendment to the plan that increased the number of shares reserved for issuance by 5,831,500, effective March 25, 2024, and an automatic increase of 2,000,000 shares effective April 1, 2024. The registration statement incorporates by reference several previously filed documents, including the company's Annual Report on Form 10-K for the year ended December 31, 2023, and various Current Reports on Form 8-K. The validity of the common stock covered by this prospectus has been passed upon by The Loev Law Firm, PC. The CEO and Chairman of Mangoceuticals, Jacob D. Cohen, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
2024年5月14日，总部位于德克萨斯州的制药公司Mangoceuticals, Inc. 向美国证券交易委员会（SEC）提交了S-8表格注册声明。该文件旨在根据公司经修订和重述的2022年股权激励计划再注册7,831,500股普通股。此举是在对该计划进行修正之后采取的，该修正案将预留发行的股票数量增加了5,831,500股，自2024年3月25日起生效，自2024年4月1日起自动增加200万股。注册声明以引用方式纳入了先前提交的几份文件，包括公司截至2023年12月31日止年度的10-K表年度报告以及表格8-K的各种最新报告。本招股说明书所涵盖的普通股的有效性已由Loev Law Firm, PC.Mangoceuticals首席执行官兼董事长雅各布·科恩以及其他高管和董事签署了注册声明，确认该公司遵守了提交S-8表格的要求。
2024年5月14日，总部位于德克萨斯州的制药公司Mangoceuticals, Inc. 向美国证券交易委员会（SEC）提交了S-8表格注册声明。该文件旨在根据公司经修订和重述的2022年股权激励计划再注册7,831,500股普通股。此举是在对该计划进行修正之后采取的，该修正案将预留发行的股票数量增加了5,831,500股，自2024年3月25日起生效，自2024年4月1日起自动增加200万股。注册声明以引用方式纳入了先前提交的几份文件，包括公司截至2023年12月31日止年度的10-K表年度报告以及表格8-K的各种最新报告。本招股说明书所涵盖的普通股的有效性已由Loev Law Firm, PC.Mangoceuticals首席执行官兼董事长雅各布·科恩以及其他高管和董事签署了注册声明，确认该公司遵守了提交S-8表格的要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息